All In Biotech

Drug Trial Radar · NCT06158698

CMP-MYTHiC Trial and Registry - CardioMyoPathy With MYocarditis THerapy With Colchicine

Single-blinded Randomized Investigator-initiated Controlled Trial to Assess the Efficacy of Colchicine to Treat Patients With Cardiomyopathy With Myocarditis (Chronic Inflammatory Cardiomyopathy)

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Nov 14, 2023

Primary completion

Mar 2, 2029

Study completion Aug 31, 2029

Sponsor

Lead sponsor
Niguarda HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
European Union; Ministry of Health, Italy; Mario Negri Institute for Pharmacological Research; University of Milano Bicocca
First posted
Dec 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Two-parallel groups randomized, single-blinded, multi-center phase III controlled trial in patients with chronic inflammatory cardiomyopathy to assess the efficacy of colchicine and associated prospective registry to assess the prognostic value of positive genetic testing in this population.

Conditions

  • Cardiomyopathies
  • Myocarditis
  • Inflammatory Cardiomyopathy
  • Heart Failure
  • Ventricular Arrythmia

Interventions

  • ColchicineDrug

    Colchicine 1 mg daily (or 0.5 mg daily il weight \<70 kg) from randomization for 180 days (6 months)

  • PlaceboOther

    Placebo 1 mg daily (or 0.5 mg daily il weight \<70 kg) from randomization for 180 days (6 months)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Patients alive and free of any worsening features (clinical, arrhythmic burden and imaging outcome) AND that show at least one of the signs of improvements (IMAGING or ARRHYTMIC improvements).Time frame: 6 months from randomization
  2. Worsening imaging outcomesTime frame: 6 months from randomization

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Centro Cardiologico Monzino

    Milan, Italy · Recruiting

  • Ospedale S.Spirito di Sassia

    Roma, Italy · Recruiting

  • Università degli studi della Campania L.Vanvitelli e Azienda Ospedaliera Specialistica dei Colli - Ospedale Monaldi

    Naples, Campania, Italy · Recruiting

  • Policlinico S.Orsola-Malpighi

    Bologna, Emilia-Romagna, Italy · Recruiting

  • Azienda Sanitaria Universitaria Integrata Giuliano Isontina, Trieste

    Trieste, Friuli Venezia Giulia, Italy · Recruiting

  • Presidio Ospedaliero Universitario "Santa Maria della Misericordia"

    Udine, Friuli Venezia Giulia, Italy · Recruiting

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    Rome, Lazio, Italy · Recruiting

  • IRCCS Ospedale San Raffaele

    Milan, Lombardy, Italy · Recruiting

  • ASST Grande Ospedale Metropolitano Niguarda

    Milan, Lombardy, Italy · Recruiting

  • Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino

    Turin, Piedmont, Italy · Recruiting

  • Università Politecnica delle Marche e AOU Ospedali Riuniti Umberto I°-Lancisi-Salesi , Ancona

    Ancona, The Marches, Italy · Recruiting

  • ASL8 Arezzo San Donato Hospital

    Arezzo, Tuscany, Italy · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.